Literature DB >> 9456487

Sir James Black and propranolol. The role of the basic sciences in the history of cardiovascular pharmacology.

M P Stapleton1.   

Abstract

The history of cardiology encompasses some of the most revered names in medical history, many belonging to physicians who have advanced knowledge beyond their time. However, there have been countless others whose work in the basic sciences has paid large dividends to clinical cardiology. The original example of such an individual is William Harvey, whose reasoned experimentation led to the understanding of the circulation of blood. Another such man, Sir James Black, has contributed to basic scientific and clinical knowledge in cardiology, both as a physician and as a basic scientist. His invention of propranolol, the beta adrenergic receptor antagonist that revolutionized the medical management of angina pectoris, is considered to be one of the most important contributions to clinical medicine and pharmacology of the 20th century. His method of research, his discoveries about adrenergic pharmacology, and his clarification of the mechanisms of cardiac action are all strengths of his work. In 1988, he was awarded the Nobel Prize in Medicine. Sir James's conclusions and method of research have continued to influence work in clinical pharmacology and cardiovascular medicine. Thus, the development of propranolol runs parallel to most other great achievements in medicine: the genius of a few builds on the accomplishments of many, and the discovery influences thinking long after the breakthrough has occurred.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9456487      PMCID: PMC325477     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  12 in total

1.  Ahlquist and the development of beta-adrenoceptor antagonists.

Authors:  J W Black
Journal:  Postgrad Med J       Date:  1976       Impact factor: 2.401

Review 2.  Beta-blockade and mechanisms of disease.

Authors:  J D Fitzgerald
Journal:  Postgrad Med J       Date:  1976       Impact factor: 2.401

3.  Pharmacology of a new adrenergic beta-receptor-blocking compound (Nethalide).

Authors:  J W BLACK; J S STEPHENSON
Journal:  Lancet       Date:  1962-08-18       Impact factor: 79.321

4.  Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol.

Authors:  C E POWELL; I H SLATER
Journal:  J Pharmacol Exp Ther       Date:  1958-04       Impact factor: 4.030

Review 5.  A personal view of pharmacology.

Authors:  J Black
Journal:  Annu Rev Pharmacol Toxicol       Date:  1996       Impact factor: 13.820

Review 6.  Drugs from emasculated hormones: the principle of syntopic antagonism.

Authors:  J Black
Journal:  Science       Date:  1989-08-04       Impact factor: 47.728

7.  Medical history and the cardiologist.

Authors:  J A Callahan
Journal:  Int J Cardiol       Date:  1988-04       Impact factor: 4.164

8.  The history of cardiology--is it important today?

Authors:  R E Vlietstra
Journal:  Clin Cardiol       Date:  1995-07       Impact factor: 2.882

9.  Adrenergic receptors: a personal and practical view.

Authors:  R P Ahlquist
Journal:  Perspect Biol Med       Date:  1973       Impact factor: 1.416

Review 10.  Propranolol in the treatment of angina: a review.

Authors:  B N Prichard
Journal:  Postgrad Med J       Date:  1976       Impact factor: 2.401

View more
  20 in total

Review 1.  Explanatory models are needed to integrate RCT and observational data with the patient's unique biology.

Authors:  Vijay Sharma; Rubin Minhas
Journal:  J R Soc Med       Date:  2012-01       Impact factor: 5.344

2.  Morphological Effects Induced In Vitro by Propranolol on Human Erythrocytes.

Authors:  Mario Suwalsky; Pablo Zambrano; Fernando Villena; Marcela Manrique-Moreno; María José Gallardo; Malgorzata Jemiola-Rzeminska; Kazimierz Strzalka; Ana María Edwards; Sigrid Mennickent; Nathan Dukes
Journal:  J Membr Biol       Date:  2015-02-28       Impact factor: 1.843

3.  The Jeremiah Metzger Lecture: Evolution of management of acute coronary syndromes (unstable angina/non ST elevation myocardial infarction).

Authors:  C Richard Conti
Journal:  Trans Am Clin Climatol Assoc       Date:  2005

Review 4.  [Prophylaxis and therapy of post-traumatic stress disorder with propranolol: evidence and ethical analysis].

Authors:  K Kühlmeyer; R J Jox
Journal:  Nervenarzt       Date:  2013-10       Impact factor: 1.214

Review 5.  Local cAMP signaling in disease at a glance.

Authors:  Matthew G Gold; Tamir Gonen; John D Scott
Journal:  J Cell Sci       Date:  2013-10-15       Impact factor: 5.285

Review 6.  Current and future status of beta-blockers in the treatment of hypertension.

Authors:  Steven G Chrysant; George S Chrysant; Billy Dimas
Journal:  Clin Cardiol       Date:  2008-06       Impact factor: 2.882

7.  Beta-blockers, hypertension, and stroke outcomes.

Authors:  Magnus O Wijkman
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-03-09       Impact factor: 3.738

Review 8.  Evaluating the Safety Profile of Non-Active Implantable Medical Devices Compared with Medicines.

Authors:  Josep Pane; Preciosa M Coloma; Katia M C Verhamme; Miriam C J M Sturkenboom; Irene Rebollo
Journal:  Drug Saf       Date:  2017-01       Impact factor: 5.606

9.  Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence.

Authors:  Qiang Xiao; Qin Li; Bin Zhang; Wenlin Yu
Journal:  Pediatr Surg Int       Date:  2013-03-22       Impact factor: 1.827

Review 10.  The genetically encoded tool set for investigating cAMP: more than the sum of its parts.

Authors:  Neha Patel; Matthew G Gold
Journal:  Front Pharmacol       Date:  2015-08-06       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.